Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial-Reference-Cited by-同舟云学术

Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial

Published:2011-12 Issue:12 Volume:11 Page:907-915
ISSN:1473-3099
Container-title:The Lancet Infectious Diseases
language:en
Short-container-title:The Lancet Infectious Diseases

Author:

Eron Joseph J,Rockstroh Jürgen K,Reynes Jacques,Andrade-Villanueva Jaime,Ramalho-Madruga Jose Valdez,Bekker Linda-Gail,Young Benjamin,Katlama Christine,Gatell-Artigas Jose Maria,Arribas Jose R,Nelson Mark,Campbell Havilland,Zhao Jing,Rodgers Anthony J,Rizk Matthew L,Wenning Larissa,Miller Michael D,Hazuda Daria,DiNubile Mark J,Leavitt Randi,Isaacs Robin,Robertson Michael N,Sklar Peter,Nguyen Bach-Yen

Publisher

Elsevier BV

Subject

Infectious Diseases

Reference27 articles.

1. HIV-1 integrase inhibitors that compete with the target DNA substrate define a unique strand transfer conformation for integrase;Espeseth;Proc Natl Acad Sci USA,2000

2. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells;Hazuda;Science,2000

3. Integrase inhibitors and cellular immunity suppress retroviral replication in rhesus macaques;Hazuda;Science,2004

4. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection;Cooper;N Engl J Med,2008

5. Raltegravir with optimized background therapy for resistant HIV-1 infection;Steigbigel;N Engl J Med,2008

Cited by 176 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Plasma Human Immunodeficiency Virus 1 RNA and CD4+ T-Cell Counts Are Determinants of Virological Nonsuppression Outcomes With Initial Integrase Inhibitor-Based Regimens: A Prospective RESPOND Cohort Study;Clinical Infectious Diseases;2023-04-13

2. Contribution of Low CD4 Cell Counts and High Human Immunodeficiency Virus (HIV) Viral Load to the Efficacy of Preferred First-Line Antiretroviral Regimens for Treating HIV Infection: A Systematic Review and Meta-Analysis;Clinical Infectious Diseases;2023-03-28

3. Relationship between raltegravir trough plasma concentration and virologic response and the impact of therapeutic drug monitoring during pregnancy;International Journal of STD & AIDS;2022-12-18

4. BHIVA guidelines on antiretroviral treatment for adults living with HIV‐1 2022;HIV Medicine;2022-12

5. An up-to-date evaluation of dolutegravir/abacavir/lamivudine for the treatment of HIV;Expert Opinion on Pharmacotherapy;2022-01-24